Literature DB >> 16317315

Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course.

Jonas Eberhard1, Eva Lindström, Sten Levander.   

Abstract

The present study comprised a naturalistic, multicentre, 5-year study of course and correlates of tardive dyskinesia (TD). One hundred and sixty-six patients treated with risperidone were included during 1995/96 and followed once a year for 5 years. Mean age at inclusion was 38 years, and mean illness duration was 12 years. Tardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale, and each patient's cognitive function was tested with a comprehensive computerised test battery. At study entry, 14% had TD according to a criterion index. Fifty percent were aware of it, but few reported distress. Age and sex did not correlate with TD, but schizophrenia and bipolar diagnoses did. The presence and intensity of TD correlated with all Positive and Negative Syndrome Scale for Schizophrenia symptom dimensions except the affective factor, but not with type of medication or chlorpromazine-equivalent levels. Tardive dyskinesia patients were cognitively impaired in tests reflecting mental speed, but not in other cognitive modalities. Over the 453 patient years of exposure, five patients developed TD and 14 became free of it. Our findings support the view that TD: (i) is a dynamic phenomenon; (ii) is only partly drug-induced; (iii) has a mild course during treatment with modern neuroleptics; and (iv) appears to have some correlation with mental slowness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16317315     DOI: 10.1097/01.yic.0000182120.51672.7d

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  7 in total

1.  Extrapyramidal side-effects of antipsychotics in a randomised trial.

Authors:  Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  Br J Psychiatry       Date:  2008-10       Impact factor: 9.319

Review 2.  [Antipsychotic-induced tardive syndromes].

Authors:  W Wolfgang Fleischhacker; Alex Hofer; Christian Jagsch; Walter Pirker; Georg Psota; Hans Rittmannsberger; Klaus Seppi
Journal:  Neuropsychiatr       Date:  2016-08-31

3.  Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Authors:  Stanley N Caroff; Vicki G Davis; Del D Miller; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; E Cabrina Campbell; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2010-08-10       Impact factor: 4.384

4.  The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.

Authors:  Daniel M Blumberger; Benoit H Mulsant; Dora Kanellopoulos; Ellen M Whyte; Anthony J Rothschild; Alastair J Flint; Barnett S Meyers
Journal:  J Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.153

Review 5.  Treatment of neurolept-induced tardive dyskinesia.

Authors:  Stacey K Jankelowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-16       Impact factor: 2.570

6.  The effects of valbenazine on tardive dyskinesia in older and younger patients.

Authors:  Martha Sajatovic; George S Alexopoulos; Joshua Burke; Khodayar Farahmand; Scott Siegert
Journal:  Int J Geriatr Psychiatry       Date:  2019-10-31       Impact factor: 3.485

7.  Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.

Authors:  Cheng-Ta Li; Kun-Hsien Chou; Tung-Ping Su; Chu-Chung Huang; Mu-Hong Chen; Ya-Mei Bai; Ching-Po Lin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.